A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Inclusion Criteria: * Patients must have completed surgical treatment for his/her primary disease at least 1 month prior to enrollment * Patient must not be pregnant 3 days prior to enrollment Exclusion Criteria: * Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent * Patient has had their spleen removed or has a history of autoimmune disorders * Patient is a regular user of any illicit drugs or has used within the past year of drug or alcohol abuse * Patient is pregnant or breastfeeding or is expecting to conceive anytime following the study * Patient is known to be Human Immunodeficiency Virus (HIV)-seropositive * Patient has a known history of Hepatitis B or C * Patient has received a vaccine for any disease or condition within one month of enrollment * Patient has a primary central nervous system tumor.